Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Tapan M. Kadia"'
Autor:
Patrick W. Burke, Stephen M Clark, Marissa Olson, Tapan M. Kadia, Dale L. Bixby, Carissa Treptow, Shawn Griffin, Bernard L. Marini, Kelley L Ratermann, Caitlin R. Rausch, Lydia L. Benitez, Mallory Crain, Anthony J. Perissinotti, Kristen Pettit, Michael Filtz, Jeff Klaus
Publikováno v:
Leukemia & Lymphoma. 62:2184-2192
Liposomal daunorubicin/cytarabine (CPX-351) gained FDA approval for secondary AML after demonstrating improved outcomes over daunorubicin and cytarabine (7 + 3). A number of study limitations prompted a comparison of safety/efficacy of CPX-351 agains
Autor:
Tapan M. Kadia, Mahran Shoukier, Courtney D. DiNardo, Elizabeth J. Shpall, Naval Daver, Kayleigh Marx, Sherry Pierce, Naveen Pemmaraju, Michael Andreeff, Rashmi Kanagal-Shamanna, Guillermo Montalban-Bravo, Sangeetha Venugopal, Nicholas J. Short, Guillermo Garcia-Manero, Gautam Borthakur, Uday R. Popat, Farhad Ravandi, Koji Sasaki, Marina Konopleva, Hagop M. Kantarjian
Publikováno v:
CancerReferences. 127(19)
Background Venetoclax (VEN) in combination with a hypomethylating agent (HMA) has become the standard of care for patients aged >75 years and for those not eligible for intensive chemotherapy who have newly diagnosed acute myeloid leukemia (AML). The
Autor:
Nicholas J. Short, Musa Yilmaz, Naval Daver, Courtney D. DiNardo, Tapan M. Kadia, Guillermo Garcia Manero, Sanam Loghavi, Hagop M. Kantarjian, Jorge E. Cortes, Rashmi Kanagal-Shamanna, Issa Ghayas, Sherry Pierce, Guillermo Montalban-Bravo, Ahmad S. Alotaibi, Farhad Ravandi, Mansour Alfayez, Rita Assi, Naveen Pemmaraju, Marina Konopleva, Michael Andreeff, Koichi Takahashi, Keyur P. Patel, Elias Jabbour, Gautam Borthakur, Maro Ohanian
Publikováno v:
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-2 (2021)
An amendment to this paper has been published and can be accessed via the original article.
Autor:
Michael Andreeff, Zeev Estrov, Maria Rhona Pinsoy, Naval Daver, Yesid Alvarado, Naveen Pemmaraju, Marina Konopleva, Lianchun Xiao, Tapan M. Kadia, Farhad Ravandi, Hagop M. Kantarjian, Sherry Pierce, Alessandra Ferrajoli, Jorge E. Cortes, Guillermo Garcia-Manero, Gautam Borthakur, Mahesh Swaminathan, Mark J. Levis, Courtney D. DiNardo, Maro Ohanian, Veronica A Guerra, Elias Jabbour, William G. Wierda, Nitin Jain
Publikováno v:
Haematologica
FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) mutation in acute myeloid leukemia (AML) is associated with poor prognosis. We hypothesized that quizartinib, a selective and potent FLT3 inhibitor, with azacitidine (AZA) or low-dose
Autor:
Srdan Verstovsek, Philip A. Thompson, Naval Daver, William G. Wierda, Tapan M. Kadia, Nitin Jain, Bouthaina S. Dabaja, Naveen Pemmaraju, Marina Konopleva, Courtney D. DiNardo, Farhad Ravandi, Hagop M. Kantarjian, Guillermo Garcia-Manero, Elias Jabbour, Caitlin R. Rausch, Mary Alma Welch, Guillermo Montalban Bravo, Shilpa Paul
Publikováno v:
Acta Haematologica
The coronavirus disease 2019 (COVID-19) pandemic poses several challenges to the management of patients with leukemia. The biology of each leukemia and its corresponding treatment with conventional intensive chemotherapy, with or without targeted the
Autor:
Jan A. Burger, Philip A. Thompson, Gautam Borthakur, Zeev Estrov, Naval Daver, Courtney D. DiNardo, Paolo Strati, Tapan M. Kadia, Christine B. Peterson, Alessandra Ferrajoli, Michael J. Keating, Elias Jabbour, William G. Wierda, Nitin Jain, Jeff L. Jorgensen, Susan O'Brien
Publikováno v:
Leukemia
Achieving undetectable MRD (U-MRD) status after chemoimmunotherapy predicts longer progression-free and overall survival. The predictive factors and timing of relapse in patients with U-MRD and value of interim MRD analysis are ill-defined. This was
Autor:
Naval Daver, Zeev Estrov, Qiao Wei, Elias Jabbour, Simon Abi Aad, Farhad Ravandi, Simona Colla, Paolo Strati, Yue Wei, Guillermo Garcia-Manero, Susan O'Brien, Courtney D. DiNardo, Tapan M. Kadia, Jianhua Hu, Monica Cabrero, Gautam Borthakur, William G. Wierda, Carlos E. Bueso-Ramos, Hagop M. Kantarjian, Jorge E. Cortes, Nicholas J. Short
Publikováno v:
American Journal of Hematology. 92:351-358
Two hundred and sixteen consecutive patients with MDS and abnormal karyotype treated with hypomethylating agents between 4/04 and 10/12 were reviewed. Median follow-up was 17 months. Using IWG criteria, best responses were complete response (CR) in 7
Autor:
Sherry Pierce, Lingsha Zhou, Graciela M. Nogueras-Gonzalez, Gautam Borthakur, Rita Assi, Naveen Pemmaraju, Srdan Verstovsek, Keyur P. Patel, Courtney D. DiNardo, Romany Gergis, Rajyalakshmi Luthra, Elias Jabbour, Prithviraj Bose, Guillermo Garcia-Manero, Juliana E. Hidalgo-Lopez, Carlos E. Bueso-Ramos, Hagop M. Kantarjian, Jorge E. Cortes, Carla Tuttle, Xuemei Wang, Zeev Estrov, Naval Daver, Tapan M. Kadia
Publikováno v:
American journal of hematology. 93(2)
Ruxolitinib and azacytidine target distinct disease manifestations of myelodysplastic syndrome/myeloproliferative neoplasms (MDS/MPNs). Patients with MDS/MPNs initially received ruxolitinib BID (doses based on platelets count), continuously in 28-day
Autor:
Farhad Ravandi, Guillermo Garcia-Manero, Marina Konopleva, Naval Daver, Kapil N. Bhalla, Michael Andreeff, Naveen Pemmaraju, Mahran Shoukier, Tapan M. Kadia, Christopher B. Benton, Courtney D. DiNardo, Gautam Borthakur, Guillermo Montalban-Bravo, Elias Jabbour, Hagop M. Kantarjian, Jorge E. Cortes, Nicholas J. Short
Publikováno v:
Journal of Clinical Oncology. 37:7034-7034
7034 Background: Mutations in TP53 are associated with low response rates to standard therapy and poor outcomes in patients (pts) with acute myeloid leukemia (AML). Combination therapy with the BCL2 inhibitor venetoclax (VEN) has emerged as an effect
Autor:
Koichi Takahashi, Prithviraj Bose, Musa Yilmaz, Courtney D. DiNardo, Naveen Garg, Zeev Estrov, Rashmi Kanagal-Shamanna, Philip A. Thompson, Chongjuan Wei, Nichole Cruz, Varsha Gandhi, Tapan M. Kadia, Xuemei Wang, Keyur P. Patel, Nathan Fowler, Elias Jabbour, Katrina Sondermann, Alessandra Ferrajoli, Ana Ayala, Jeffrey L. Jorgensen, Naveen Pemmaraju, Jan A. Burger, Koji Sasaki, William G. Wierda, Hagop M. Kantarjian, Nitin Jain, Yesid Alvarado, Maro Ohanian, William Plunkett, Marina Konopleva, Michael J. Keating, Gautam Borthakur
Publikováno v:
Blood. 132:696-696
Background: Ibrutinib (IBR), a BTK inhibitor, and venetoclax (VEN), a BCL-2 inhibitor are approved for patients (pts) with CLL. The rationale for combining IBR and VEN includes: 1) preclinical models showing synergism with the combination, 2) non-ove